Atossa Therapeutics Past Earnings Performance
Past criteria checks 0/6
Atossa Therapeutics's earnings have been declining at an average annual rate of -13.7%, while the Biotechs industry saw earnings growing at 13.4% annually.
Key information
-13.7%
Earnings growth rate
56.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -32.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Atossa Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -26 | 13 | 17 |
| 31 Mar 24 | 0 | -30 | 14 | 18 |
| 31 Dec 23 | 0 | -30 | 14 | 17 |
| 30 Sep 23 | 0 | -30 | 14 | 17 |
| 30 Jun 23 | 0 | -32 | 14 | 17 |
| 31 Mar 23 | 0 | -28 | 13 | 17 |
| 31 Dec 22 | 0 | -27 | 13 | 15 |
| 30 Sep 22 | 0 | -24 | 12 | 12 |
| 30 Jun 22 | 0 | -21 | 12 | 9 |
| 31 Mar 22 | 0 | -22 | 12 | 9 |
| 31 Dec 21 | 0 | -21 | 11 | 9 |
| 30 Sep 21 | 0 | -28 | 10 | 10 |
| 30 Jun 21 | 0 | -26 | 9 | 9 |
| 31 Mar 21 | 0 | -23 | 8 | 7 |
| 31 Dec 20 | 0 | -22 | 8 | 7 |
| 30 Sep 20 | 0 | -13 | 8 | 5 |
| 30 Jun 20 | 0 | -13 | 8 | 5 |
| 31 Mar 20 | 0 | -16 | 10 | 6 |
| 31 Dec 19 | 0 | -17 | 11 | 7 |
| 30 Sep 19 | 0 | -17 | 10 | 7 |
| 30 Jun 19 | 0 | -17 | 10 | 6 |
| 31 Mar 19 | 0 | -25 | 8 | 5 |
| 31 Dec 18 | 0 | -23 | 7 | 4 |
| 30 Sep 18 | 0 | -23 | 7 | 4 |
| 30 Jun 18 | 0 | -22 | 7 | 3 |
| 31 Mar 18 | 0 | -11 | 5 | 2 |
| 31 Dec 17 | 0 | -11 | 5 | 2 |
| 30 Sep 17 | 0 | -11 | 5 | 2 |
| 30 Jun 17 | 0 | -9 | 5 | 2 |
| 31 Mar 17 | 0 | -6 | 5 | 1 |
| 31 Dec 16 | 0 | -6 | 6 | 1 |
| 30 Sep 16 | 0 | -6 | 7 | 1 |
| 30 Jun 16 | 0 | -10 | 9 | 2 |
| 31 Mar 16 | 0 | -12 | 10 | 2 |
| 31 Dec 15 | 0 | -13 | 10 | 2 |
| 30 Sep 15 | 0 | -13 | 10 | 1 |
| 30 Jun 15 | 0 | -13 | 10 | 1 |
| 31 Mar 15 | 0 | -13 | 9 | 1 |
| 31 Dec 14 | 0 | -12 | 9 | 1 |
| 30 Sep 14 | 0 | -12 | 9 | 2 |
| 30 Jun 14 | 0 | -12 | 10 | 1 |
| 31 Mar 14 | 0 | -11 | 10 | 1 |
| 31 Dec 13 | 1 | -11 | 10 | 1 |
Quality Earnings: YAG2 is currently unprofitable.
Growing Profit Margin: YAG2 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YAG2 is unprofitable, and losses have increased over the past 5 years at a rate of 13.7% per year.
Accelerating Growth: Unable to compare YAG2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YAG2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16%).
Return on Equity
High ROE: YAG2 has a negative Return on Equity (-32.32%), as it is currently unprofitable.